Transfusion-associated Hepatitis E, France

To the Editor: Hepatitis E virus (HEV) is a leading cause of acute and fulminant hepatitis in developing countries (1). In industrialized countries, HEV seroprevalence rates of 0.4%–3% are common, and evidence is mounting that autochthonous transmission might account for a substantial proportion of infections (1–3). Whereas fecal-oral HEV transmission is preponderant in developing countries, other routes have been demonstrated in industrialized countries, among them consumption of pork or boar meat (1,4). Parenteral transmission was first suggested but not demonstrated (5,6). Because viruses cannot be fully inactivated in blood products, HEV recently emerged as a transfusion-transmitted pathogen, with 6 reported cases, including 3 in transfusion-transmitted pathogen, products, HEV recently emerged as a cannot be fully inactivated in blood donation, which indicates that the blood donation occurred during the prodromic phase of HEV disease. HEV nucleotide sequences from the blood donor and recipient were identical. Phylogenetic analysis showed that they clustered together and were closely related to genotype 3f, which is prevalent in Europe (Figure [8]).

The blood donor was a 24-year-old man. He did not travel outside metropolitan France for 8 months before donating blood. Anti-HEV IgG seroconversion was observed on a serum sample collected 24 weeks after blood donation, whereas anti-HEV IgM and serum HEV RNA test negative. ALT levels were within normal values at the time of blood donation and 24 weeks later. No clinical signs were reported at any time. No other recipient received blood products from this donor.

Our data show that HEV was transmitted from 1 blood donor to the recipient child. On the basis of retrospective HEV RNA detection, 6 other transfusion-transmitted HEV infections, all involving adult blood recipients, have occurred in HEV-hyperendemic and industrialized countries (7). Transfusion-transmitted HEV strains belonged to different genotypes/subtypes that corresponded to those found in the same geographic areas (Figure).

In France, neither HEV antibodies nor HEV RNA are systematically tested in blood donors, and blood donations currently are not tested for ALT. In the absence of systematic HEV RNA testing, HEV diagnosis in blood donations may be hampered by HEV viremia before clinical onset and anti-HEV seroconversion, the possible short persistence or absence of HEV antibodies, and the high frequency of subclinical infections.
LETTERS

(1,2,5). On the basis of these data, improved knowledge of HEV epidemiology in the general population and in blood donors is needed in industrialized countries to guide HEV screening policy for blood products.

Another concern of transfusion-transmitted HEV infections is the potential severity of acute hepatitis E. Previously reported cases of contamination through transfusion and our case showed spontaneous recovery. However, although typically self-limited, hepatitis E is potentially life-threatening with mortality rates of 0.2%–4%, reaching 20% in pregnant women (1). Fatal outcome has also been described in children (9). In summary, HEV-contaminated blood donations are a challenge for diagnosis and virus safety of transfusion, including in industrialized countries.

Acknowledgments

We are indebted to Didier Raoult for his valuable comments and support and also to Dominique Legrand and Sophie Simon for their participation in the transfusion investigation.

Philippe Colson,*† Carole Coze,* Pierre Gallian,†‡ Mireille Henry,** Philippe De Micco,†‡ and Catherine Tamalet††

*Centre Hospitalier Régional Universitaire, Timone, Marseille, France; †Université de la Méditerranée, Marseille, France; and ‡Établissement Français du Sang Alpes–Méditerranée, Marseille, France

References

1. Worm HC, van der Poel WH, Brandstatter G. Hepatitis E: an overview. Microbes Infect. 2002;4:657–66.
2. Peron JM, Mansuy JM, Poisson H, Bureau C, Dupuis E, Alric L, et al. Hepatitis E is an autochthonous disease in industrialized countries. Analysis of 23 patients in South-West France over a 13-month period and comparison with hepatitis A. Gastroenterol Clin Biol. 2006;30:757–62.
3. Ijaz S, Arnold E, Banks M, Bendall RP, Cramp ME, Cunningham R, et al. Non-travel-associated hepatitis E in England and Wales: demographic, clinical, and molecular epidemiological characteristics. J Infect Dis. 2005;192:1166–72.
4. Lu L, Li C, Hagedorn CH. Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev Med Virol. 2006;16:5–36.
5. Arora NK, Nanda SK, Gulati S, Ansari IH, Chawla MK, Gupta SD, et al. Acute viral hepatitis types E, A, and B singly and in combination in acute liver failure in children in north India. J Med Virol. 1996;48:215–21.

Address for correspondence: Philippe Colson, Laboratoire de Virologie, Fédération Hospitalière de Bactériologie–Virologie Clinique et d’Hygiène, CHRU Timone, 264 rue Saint-Pierre 13385, Marseille CEDEX 05, France; email address: philippe.colson@ap-hm.fr

Figure. Outline of phylogenetic tree constructed by the neighbor-joining method based on partial nucleotide sequences of the open reading frame (ORF) 2 region of hepatitis E virus (HEV) genome obtained from the blood donor and blood recipient, with sequences of other local HEV strains previously identified and published HEV sequences (8). Bootstrap values are indicated when >50% as a percentage obtained from 100 resamplings of the data. Black squares indicate HEV sequences from the blood donor and recipient (GenBank accession nos. EF028801 and EF028802); white squares indicate HEV sequences from other individuals with hepatitis E living in Marseille and environs; white triangles indicate HEV sequences from the United Kingdom (3) that have an 80%–100% homology at the nucleotide level with those obtained by Boxall et al. (7). See online figure, available at http://www.cdc.gov/content/EID/13/4/648-G.htm, for complete phylogenetic tree and details of methods and sequences.